Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Neuren: A$10.1m Non-renounceable Rights Issue

Neuren Announces A$10.1 Million Non-renounceable Rights Issue

Neuren Pharmaceuticals Limited (ASX: NEU) advises that it will undertake a non-renounceable rights issue to raise up to A$10.1 million.

The rights issue will be offered to shareholders on the basis of one new share for every two shares held on the record date of 2 January 2008, at a subscription price of A$0.14 per share for Australian resident shareholders and the New Zealand dollar equivalent of NZ$0.16 per share for New Zealand resident shareholders.

The Company has entered into an underwriting agreement with respect to the rights issue whereby Taylor Collison Limited has agreed to underwrite the issue of 50.7 million shares, ensuring that the issue will raise a minimum of $7.1 million before costs.

The underwritten amount of A$7.1 million will support Glypromate® clinical trial costs and overhead through 2008. The full A$10.1 million will support completion of the Glypromate® Phase 3 trial as well as associated overhead and corporate operating expenses. The Glypromate® Phase 3 trial is proceeding to plan.

Neuren has a number of licensing and joint venture initiatives underway both locally and internationally to assist in the funding required to ensure that the Company’s pipeline of other lead compounds moves through to the next stage of clinical trials during CY08. The Directors have decided that until such funding is available, the primary focus of the Company will be the completion of the current Phase 3 Glypromate® trial.

A shortfall facility has also been included in the Offer for those who wish to subscribe for more than their entitlement.

Option holders will not be entitled to participate in the offer unless they exercise and are
registered by the record date of 2 January 2008.

Full details of the rights issue are contained in a Letter of Offer (for Australian resident shareholders) and an Investment Statement and Prospectus (for New Zealand resident shareholders) that will be lodged with ASX Limited later today.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of brain injury, neurological diseases and metabolic disorders. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has four lead candidate molecules—Glypromate®, MotivaTM, NNZ-2566 and NNZ-2591—focused on a range of acute and chronic neurological conditions. The company also has a robust R&D program which includes drug discovery platforms addressing neurology, oncology and endocrinology.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Half Full: Fonterra Raises Forecast Payout As Global Supply Shrinks

Fonterra Cooperative Group, the dairy processor which will announce annual earnings tomorrow, hiked its forecast payout to farmers by 50 cents per kilogram of milk solids as global supply continues to decline, helping prop up dairy prices. More>>

ALSO:

Results:

Meat Trade: Silver Fern Farms Gets Green Light For Shanghai Maling Deal

The government has given the green light for China's Shanghai Maling Aquarius to acquire half of Silver Fern Farms, New Zealand's biggest meat company, with ministers satisfied it will deliver "substantial and identifiable benefit". More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news